Cellgebra

We are an Irish startup committed to cancer drug discovery

Cellgebra has received significant funding from Enterprise Ireland.  Together with Royal College of Surgeons in Ireland, we are developing a digital solution to aid rational oncology drug discovery. Presently, a large source of drug failure (40 to 80%) in clinical trials is the lack of efficacy, which is linked to poor understanding of the molecular mechanisms causing disease and corresponding incorrect identification of targets and responsive patient populations. Reliable pre-clinical models remain difficult to establish and expensive for high volume testing. Our platform offers an alternative by simulating cell response to a given drug in a specific cancer based on digital copy of cell signalling pathways. It will enable a wide range of quick and low cost in silico experiments for different patient populations that will provide value across drug development cycle:

• identify new drug targets

• test potential drug lead candidates based on specific on and off target profile

• identify responsive patient populations

• identify promising drug combinations

• predict future resistance mechanisms

The digital twins are build using proprietary algorithms and datasets generated using patient derived cell lines grown in 3D culture.